US FDA approves pills for postpartum depression

The US Food and Drug Administration (FDA) on Friday approved Biogen and Sage Therapeutics’ oral pill to treat postpartum depression (PPD) in adults.

The companies had sought the FDA’s approval for the drug, Zurzuvae, to treat major depressive disorder (MDD), or clinical depression, as well as postpartum depression, which affect millions of people.

PPD severely affects a woman’s ability to return to normal functioning, while also potentially affecting the mother’s relationship with her child.

“Zurzuvae is expected to launch and be commercially available in the fourth quarter of 2023 shortly following scheduling as a controlled substance by the U.S. Drug Enforcement Administration, which is anticipated to occur within 90 days,” Sage Therapeutics and Biogen said in a statement.

More from World

India’s US envoy Kwatra discusses bilateral trade ties with US lawmakers Netanyahu accuses Hamas leaders of derailing ceasefire, says eliminating them in Qatar could end Gaza war

The statement said the FDA issued a Complete Response Letter for the New Drug Application for Zurzuvae in the treatment of adults with MDD. The letter said the application did not provide substantial evidence of the effectiveness of Zurzuvae for treating of MDD and that additional studies would be needed to support the approval.

Sage and Biogen said they were reviewing the feedback and evaluating the next steps.

Analysts have anticipated that the stocks of both companies would fall if the drug was approved only for postpartum depression, due to the smaller patient population.

Impact Shorts

More Shorts

‘The cries of this widow will echo’: In first public remarks, Erika Kirk warns Charlie’s killers they’ve ‘unleashed a fire’

Trump urges Nato to back sanctions on Russia, calls for 50–100% tariffs on China

Until now, the FDA said, treatment for postpartum depression was available only as an intravenous injection.

In 2021, an estimated 21 million adults in the United States had at least one episode of major depressive disorder, which is characterized by a persistent feeling of sadness. PPD affects around one in seven women who give birth.